TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03710005

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ascent
Description: Dehydrated Cell and Protein Concentrate injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Standard corticosteroid injection
Study: NCT05687175

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire administration (PDQ-M, NRS, SF-36)

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire administration (PDQ-M, NRS, SF-36)
Study: NCT03537508

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, mumps, rubella (MMR) vaccine
Description: MMR vaccine at 12 months of age, Subcutaneous
Study: NCT03761784

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S6G5T-8
Description: Once a day topical cream
Study: NCT04153344

Intervention type: OTHER
Intervention: Electro-oculogram
Description: Electrophysiological recording of changes in electrical potential across the retinal pigmentary epithelium during successive periods of dark and light adaptation, according to ISCEV standards. Results will comprise dark trough value and light/dark (Arden) ratio.

Intervention type: OTHER
Intervention: Electro-oculogram
Description: Electrophysiological recording of changes in electrical potential across the retinal pigmentary epithelium during successive periods of dark and light adaptation, according to ISCEV standards. Results will comprise dark trough value and light/dark (Arden) ratio.

Intervention type: OTHER
Intervention: Electro-oculogram
Description: Electrophysiological recording of changes in electrical potential across the retinal pigmentary epithelium during successive periods of dark and light adaptation, according to ISCEV standards. Results will comprise dark trough value and light/dark (Arden) ratio.
Study: NCT02451111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib
Description: Patients will be instructed by the Investigator to take the amount of 560 mg Ibrutinib/Placebo (4 x 140 mg capsules) orally once daily with a glass of water at approximately the same time every day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375 mg/m2 has to be administered i.v. for the first four (4) infusions in all patients. After i.v. administration of Rituximab for the induction therapy, the administration mode can be changed to s.c. (1400 mg) in the maintenance phase dependent on the local standard of care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375 mg/m2 has to be administered i.v. for the first four (4) infusions in all patients. After i.v. administration of Rituximab for the induction therapy, the administration mode can be changed to s.c. (1400 mg) in the maintenance phase dependent on the local standard of care.
Study: NCT00149734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron followed by placebo
Description: Participants will take 16mg of ondansetron daily for the first three months followed by 3 months of placebo. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo followed by Ondansetron
Description: Participants will take placebo daily for the first three months followed by 3 months of 16mg of ondansetron daily. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
Study: NCT02170194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience Enhancement Training via Smart Phone

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Daily Text Messages
Study: NCT01278836

Intervention type: PROCEDURE
Group type: OTHER
Intervention: fasciocutaneous flap
Description: flaps which include skin, subcutaneous tissue, and the underlying fascia.
Study: NCT00435864

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood test
Description: The study of KIR and HLA genes will be performed on samples of cord blood or peripheral blood donor and recipient before transplant For grafts from placental cord blood, we do ask any additional samples.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood test
Description: The study of KIR and HLA genes will be performed on samples of cord blood or peripheral blood donor and recipient before transplant For grafts from placental cord blood, we do ask any additional samples.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood test
Description: The study of KIR and HLA genes will be performed on samples of cord blood or peripheral blood donor and recipient before transplant For grafts from placental cord blood, we do ask any additional samples.
Study: NCT00154622

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: work hardening program
Study: NCT03537508

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, mumps, rubella (MMR) vaccine
Description: MMR vaccine at 12 months of age, Subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles, mumps, rubella (MMR) vaccine
Description: MMR vaccine at 12 months of age, Subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles, mumps, rubella (MMR) vaccine
Description: MMR vaccine at 12 months of age, Subcutaneous
Study: NCT04153344

Intervention type: OTHER
Intervention: Full-field electroretinogram
Description: Electrophysiological recording of retinal function. Results will comprise amplitudes and latencies of each electroretinography response (dark-adapted 0.01, dark-adapted 3.0, dark-adapted 10.0, dark-adapted 3.0 oscillatory potentials, light-adapted 3.0, light-adapted 3.0 flicker).

Intervention type: OTHER
Intervention: Full-field electroretinogram
Description: Electrophysiological recording of retinal function. Results will comprise amplitudes and latencies of each electroretinography response (dark-adapted 0.01, dark-adapted 3.0, dark-adapted 10.0, dark-adapted 3.0 oscillatory potentials, light-adapted 3.0, light-adapted 3.0 flicker).
Study: NCT03537508

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella vaccine
Description: Varicella vaccine at 12 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella vaccine
Description: Varicella vaccine at 12 months of age
Study: NCT00697788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine bolus 1 ug/kg over 10 minutes, followed by ascending infusion as follows: Dexmedetomidine \[in ug/kg/hr\], each for 15 minutes: 0.7, 1.0, 1.3, 1.6, 1.9, 2.2, 2.5.
Study: NCT03537508

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varicella vaccine
Description: Varicella vaccine at 12 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varicella vaccine
Description: Varicella vaccine at 12 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Description: Hepatitis A vaccine at 15 to 18 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine
Description: Hepatitis A vaccine at 15 to 18 months of age
Study: NCT00784017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: asparaginase
Description: 5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant asparaginase
Description: 5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
Study: NCT01001689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional counseling + exercise groups
Description: Two telephone consultations on nutritional topics and twice weekly exercise groups. Access to a password-protected internet site with information on healthy lifestyle during pregnancy. Two evening meetings with information on healthy pregnancy lifestyle.
Study: NCT04153344

Intervention type: OTHER
Intervention: Full-field electroretinogram
Description: Electrophysiological recording of retinal function. Results will comprise amplitudes and latencies of each electroretinography response (dark-adapted 0.01, dark-adapted 3.0, dark-adapted 10.0, dark-adapted 3.0 oscillatory potentials, light-adapted 3.0, light-adapted 3.0 flicker).
Study: NCT06142591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 10mg
Description: 10mg of oxycodone was added to Octenisept in the wound dressing.
Study: NCT03058783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-124 Lotion
Description: IDP-124 Lotion, twice-daily application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-124 Vehicle Lotion
Description: IDP-124 Vehicle Lotion, twice-daily application
Study: NCT06142591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 20mg
Description: 20mg of oxycodone was added to Octenisept in the wound dressing.
Study: NCT04734392

Intervention type: PROCEDURE
Intervention: TAVR
Description: TAVR implantation in cusp overlay technique
Study: NCT00573768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac diethylamine 2.32% gel
Description: Diclofenac diethylamine 2.32% gel twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle 2 times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac diethylamine 2.32% gel / Placebo
Description: Diclofenac diethylamine 2.32% gel once daily / Vehicle once daily
Study: NCT04442009

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group SCPB
Description: In group SCBP, SCBP block will be performed. Patients will be administered dexketoprofen 50 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
Study: NCT03840889

Intervention type: OTHER
Intervention: Data collection
Description: he different modes of active data collection:~* Data collection by telephone~* Data collection by mail~* Collection from discharge database summaries (PMSI)
Study: NCT02018068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote control
Description: When pain or sensory and motor block evaluation exceed the thresholds, the patient enters the data in the PCA (patient Control Analgesia) pump. The investigator is alerted by SMS on his smartphone and makes the necessary programming changes by remote control on the Micrel Care TM site. Systematic assessments via the PCA pump are scheduled for 9:00, 13:00 and 19:00 every day during 48 to 72 hours. The patient can alert his physician through his PCA pump of any additional requests (pain, motor blockade, numbness). The anesthesiologist receives an SMS alert and can make any necessary programming changes to the pump via the remote control.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: At bedside care
Description: When pain or sensory and motor block evaluation exceed the thresholds, the nurse contacts the physician and she will be able to modify the pump settings according to the anesthesiologist prescription. The delay between the call of the patient and the programming changes, the duration of the procedure are reported. Systematic evaluations via the PCA (Patient Control Analgesia) pump are done when the patient arrives in this surgical ward and at 9:00, 13:00 and 19:00 every day for 48 to 72 hours.Throughout the study, if necessary, the nurse or referring physician performs the programming changes directly on the PCA pump and notes the delay in treatment. All the reasons and the duration of any bedside visit are reported.
Study: NCT02670720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avoralstat
Study: NCT02472873

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aspiration and Sclerotherapy of endometriomas.
Description: Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cystectomy of endometriomas.
Description: cystectomy of endometriomas during laparoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Study: NCT02654314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 5 mg Melatonin nightly, beginning within 24 hours of admission
Study: NCT01991873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab (Within maintenance phase)
Study: NCT02654314

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blue capsule matching the melatonin arm
Study: NCT01991873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 (Within re-induction phase)
Study: NCT04004546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health literacy-based intervention
Description: Participants in the intervention group will receive a: i) 30-min video about medication adherence, ii) medication adherence booklet, and iii) 2-week telephone call by a nurse.
Study: NCT00594048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resperate
Description: Use of the device 15 minutes a day for 9 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: discman with freely chosen music
Description: Use the discman 15 minutes a day for 9 weeks
Study: NCT04478981

Intervention type: OTHER
Intervention: No intervention
Description: This concerns a natural history study; no interventions will be used
Study: NCT01991873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 (Within re-induction phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab (Within re-induction phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab (Within re-induction phase)
Study: NCT01827189

Intervention type: OTHER
Intervention: Comprehensive primary care
Description: Practices participating in the comprehensive primary care initiative receive a monthly amount from Centers for Medicare and Medicaid Services for each attributed Medicare patient, plus technical support of a learning collaborative, and can share in any net savings generated.
Study: NCT03427619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OK432
Description: OK432 will be injected at dosage of 0.01 to 0.05 mg/mL 6-12 weeks apart up to 4 injections total.
Study: NCT01652157

Intervention type: BIOLOGICAL
Intervention: ULTRESA
Description: pancreatic enzyme replacement therapy

Intervention type: BIOLOGICAL
Intervention: PANCREAZE
Description: pancreatic enzyme replacement therapy

Intervention type: BIOLOGICAL
Intervention: CREON
Description: pancreatic enzyme replacement therapy

Intervention type: BIOLOGICAL
Intervention: ZENPEP
Description: pancreatic enzyme replacement therapy

Intervention type: BIOLOGICAL
Intervention: other non-sponsor pancreatic enzyme replacement therapy
Description: pancreatic enzyme replacement therapy

Intervention type: BIOLOGICAL
Intervention: PERTZYE
Description: pancreatic enzyme replacement therapy

Intervention type: OTHER
Intervention: No pancreatic enzyme replacement therapy
Description: Cystic fibrosis patients in the cystic fibrosis registry not receiving any pancreatic enzyme replacement therapy (approximately 10%)
Study: NCT01275378

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Collaborative Care Plus
Description: Traditional collaborative care + systematic addressing of ADHD comorbidities, parental mental health issues, and adherence to treatment plans

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Collaborative Care
Description: Traditional collaborative care, in which care managers serve as intermediaries between primary care physicians and specialists
Study: NCT00709657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab, bevacizumab or pegaptanib
Description: measurements are performed one week before and after anti-VEGF intravitreal injection
Study: NCT03347669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sudoscan®
Description: Sudoscan® is a new device that provides rapid, non-invasive and reproducible quantitative assessment of sweat function. It makes it possible to measure the ability of the sweat glands to release chloride ions in response to electrochemical activation and thus to detect the presence of a neuropathy with small fibers. This new device therefore makes it possible to detect an SFN in a much simpler and faster way than the technique of ophthalmology, or biopsy. Sudoscan® has been tested to assess the neuropathies of small nerve fibers in several diseases, in particular diabetes, chemotherapy-induced polyneuropathy, familial amyloid polyneuropathy or Fabry disease. The interest of Sudoscan® lies in the fact that this device is non-invasive and rapid. Its diagnostic value has been compared with other neurophysiological tests.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sudoscan®
Description: Sudoscan® is a new device that provides rapid, non-invasive and reproducible quantitative assessment of sweat function. It makes it possible to measure the ability of the sweat glands to release chloride ions in response to electrochemical activation and thus to detect the presence of a neuropathy with small fibers. This new device therefore makes it possible to detect an SFN in a much simpler and faster way than the technique of ophthalmology, or biopsy. Sudoscan® has been tested to assess the neuropathies of small nerve fibers in several diseases, in particular diabetes, chemotherapy-induced polyneuropathy, familial amyloid polyneuropathy or Fabry disease. The interest of Sudoscan® lies in the fact that this device is non-invasive and rapid. Its diagnostic value has been compared with other neurophysiological tests.
Study: NCT06558097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XXB750
Description: Single SC dose of XXB750 (administered by single or multiple injections)
Study: NCT00556114

Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: Optical Coherence Tomography
Study: NCT01117779

Intervention type: DEVICE
Intervention: Cryoablation
Description: Cryoablation (freezing) with Galil Medical cryoablation systems and needles under imaging guidance
Study: NCT02020226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302
Description: 480 mg/m2 30 min IV infusion on Days 1, 8, and 15 of a 28 day cycle
Study: NCT04087642

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intraoperative Crede manoeuver
Description: In this group, both tests will be performed but the intraoperative Crede manoeuver will determine if an anti-incontinence procedure should be performed concomitantly. If the test is positive, it will be performed. If the test is negative, it will not be performed.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative prolapse reduction cough stress test
Description: In this group, both tests will be performed but the preoperative prolapse reduction cough stress test will determine if an anti-incontinence procedure should be performed concomitantly. If the test is positive, it will be performed. If the test is negative, it will not be performed.
Study: NCT03575013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is a fully human anti-programmed death ligand 1 (PD-L1) IgG1 antibody
Study: NCT01549652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron 8 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron 8 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to Match Ondansetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to Match Ondansetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Sustained release oral morphine, beginning at 30 mg/d, titrated up by 15 mg/d every 2 days until adequate analgesia is achieved

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Sustained release oral morphine, beginning at 30 mg/d, titrated up by 15 mg/d every 2 days until adequate analgesia is achieved

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone 0.4 mg/70 kg
Description: Naloxone 0.4 mg/70 kg intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone 0.4 mg/70 kg
Description: Naloxone 0.4 mg/70 kg intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone 0.8 mg/70 kg
Description: Naloxone 0.8 mg/70 kg intravenous
Study: NCT06558097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XXB750
Description: Single SC dose of XXB750 (administered by single or multiple injections)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XXB750
Description: Single SC dose of XXB750 (administered by single or multiple injections)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XXB750
Description: Single SC dose of XXB750 (administered by single or multiple injections)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XXB750
Description: Single SC dose of XXB750 (administered by single or multiple injections)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XXB750
Description: Single SC dose of XXB750 (administered by single or multiple injections)
Study: NCT01549652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone 0.8 mg/70 kg
Description: Naloxone 0.8 mg/70 kg intravenous
Study: NCT00586339

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Intramuscular injection, 3 doses
Study: NCT01464606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: ≥ 3 years: 1.5 mg/m2 IV x 1 (maximum dose 2 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: ≥ 3 years: 1.5 mg/m2 IV x 1 (maximum dose 2 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: ≥ 3 years: 0.045 mg/kg (maximum dose 2.5 mg) IV X 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: ≥ 3 years: 0.045 mg/kg (maximum dose 2.5 mg) IV X 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: ≥ 3 year: 1.2 gm/m2/dose IV as 1 hr infusion with IV fluids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: ≥ 3 year: 1.2 gm/m2/dose IV as 1 hr infusion with IV fluids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: ≥ 3 years: 3 g/m2/dose IV over 3 hours on Days 1, 2, (6 g/m2/cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: ≥ 3 years: 30 mg/m2/dose IV over 30 min, Days 1, 2 (60 mg/m2/cycle)